Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/11/2011

was $2.3 million, which includes $1.3 million of the $15 million paid to the Company's partner Auxilium Pharmaceuticals, Inc by Pfizer Inc. for the completion of the Marketing Authorization Application for XIAFLEX for Dupuytren's contracture in Europe.  The Company also received a milestone of $1.0 million related to the FDA's approval of XIAFLEX for Dupuytren's contracture in February 2010 and in connection with the notification in June 2010 to Auxilium of the Company's election not to commercially manufacture XIAFLEX.

Research and development expenses for the fourth quarter of 2010 were a credit of $34,256 compared to $0.1 million for the same period in 2009. This credit in research and development was mainly due to an adjustment during the quarter to the amount of third party lyophilization expenses reported to us by Auxilium. For the year ended December 31, 2010, research and development expenses were $1.2 million, compared to $0.5 million in 2009. This increase in research and development expenses was primarily due to third party development costs that are reimbursable to BioSpecifics.

General and administrative expenses for the fourth quarter of 2010 were $1.5 million, compared to $1.3 million for the same period in 2009. For the year ended December 31, 2010, general and administrative expenses were $6.5 million, compared to $4.8 million in 2009. The increase in general and administrative expenses was due to legal fees, stock based compensation and services related to investor relations partially offset by lower patent costs.

As of December 31, 2010, the Company had cash, cash equivalents and investments of $7.8 million, compared to $8.5 million on December 31, 2009.

Upcoming Milestones:

  • Auxilium anticipates reporting top-line results in the first half of 2012 for the Phase III double-blind studies of XIAFLEX for Peyronie's disease.

  • Auxilium plans to prioritize new pipeline indication(s) for XIAFL
    '/>"/>

  • SOURCE BioSpecifics Technologies Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
    2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
    3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
    4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
    5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
    6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
    7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
    8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
    9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
    10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
    11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
    (Date:12/19/2014)... 19, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... (Bina), a privately held company based in ... provides a big data platform for centralized management ... Bina,s proprietary on-market Genomic Management Solution, Bina-GMS 1 ... perform fast and scalable analyses to maximize the ...
    (Date:12/19/2014)... Dec. 19, 2014 Research and Markets ... of the "Technology Innovations in Smart Fabrics ... http://photos.prnewswire.com/prnh/20130307/600769 ... Fabrics" offers a detailed assessment on technological advancements ... Findings: 1. The Smart Fabrics ...
    (Date:12/19/2014)... LayerBio is an MIT spin-off developing novel drug ... Eye Institute (NEI) at the National Institutes of Health ... to develop a drug-eluting intraocular lens (IOL) for cataract ... vision loss in people over age 40 and the ... Mandell, LayerBio’s Founder and CEO, "There is a critical ...
    Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
    ... could improve the life of the lithium batteries ... players, and mobile phones. Research to be published ... Nanomanufacturing - demonstrates that carbon nanotubes can prevent ... time. , Researchers at the Shenyang National Laboratory ...
    ... 10 Hologic, Inc.,(Nasdaq: HOLX ) today ... presenting at the Sun Trust Robinson Humphrey,s 37th ... Ritz-Carlton Hotel in,Buckhead, GA., Interested parties are ... of,Hologic,s investor presentation on Wednesday, April 16, 2008, ...
    ... are 14 prescription drugs that,exceeded $20 billion in sales in ... in four years. Prescription to OTC switches,were frequent in 2006 ... of the Rx to OTC Switch: Market Analysis and Product ... Rx to OTC are forecast to reach $5 billion in ...
    Cached Biology Technology:Sweet nanotech batteries 2Hologic to Present at the Sun Trust Robinson Humphrey's 37th Annual Institutional Conference 2Use of Rx to OTC Switch as Product Management Tactic Enjoys Comeback 2
    (Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
    (Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
    (Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
    Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
    ... ahead of a deadly disease that has wiped out more ... continue to discover new frog species in Panama: Pristimantis ... adnus from Darien Province near the Colombian border. , ... world. Then they identified the cause: a fungal disease called ...
    ... Irvine scientists have created an eight-layer, early-stage retina from ... to be made from stem cells. It also ... retinas to treat eye disorders such as retinitis pigmentosa ... a complex structure consisting of many cell types," said ...
    ... Medicine have identified in mice a previously unknown protective ... clots and other blockages from the brain. The findings ... age-related cognitive decline, Alzheimer,s disease and recovery from stroke. ... May 27 issue of Nature by Jaime ...
    Cached Biology News:2 new frog species discovered in Panama's fungal war zone 2UCI researchers create retina from human embryonic stem cells 2Researchers discover new mechanism for clearing blockages from smallest blood vessels 2
    ... and ES1301 mutS are mismatch repair minus ... strains prevents repair of the newly synthesized ... efficiencies and making them helpful in such ... II Mutagenesis Systems. Both ES1301 and BMH ...
    Request Info...
    ... ExcelGel DNA Analysis Kit, 1. ... polymorphisms and high resolution DNA typing. ... set-up and clean-up. *Precast, plastic-backed gels ... handling convenience and detection sensitivity. ...
    For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
    Biology Products: